CD8A and neoplasm: In this research, 25-D1.16 antibody was used to specifically bind with the complex (SIINFEKL/H-2Kb) to confirm and quantify the antigen cross-presentation through the MHC class I pathway, which is necessary for inducing the formation of anti-tumor CTL CD8+ T cells (Burgdorf et al., 2007).